Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
37 articles scientifiques publiés — un praticien à la pointe de la recherche
Référence presse grand public
Cité 6 fois dans les médias — pédagogie reconnue
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
26
26 articles ont été cités au moins 26fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
h-index
Total citations reçues
4 384
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
99
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
48
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Cognitive Stability Among Plasma p-tau 181 Negative Individuals: A 5-year Analysis of the Multidomain Alzheimer Prevention Trial Study
2025ArticleJournals of Gerontology Series A: Biological Sciences and Medical Sciences
Plasma p-tau181 as an outcome and predictor of multidomain intervention effects: a secondary analysis of a randomised, controlled, dementia prevention trial
2024ArticleThe Lancet. Healthy longevity
Low circulating adropin concentrations predict increased risk of cognitive decline in community-dwelling older adults
2024ArticleGeroScience
Longitudinal Associations Between ATPase Inhibitory Factor 1, Growth Differentiation Factor-15, and Nutritional Status in Older Adults From the MAPT Study
2024ArticleJournals of Gerontology Series A: Biological Sciences and Medical Sciences
Investigating three ways of measuring the intrinsic capacity domain of vitality: nutritional status, handgrip strength and ageing biomarkers
2023ArticleAge and Ageing
TNFR-1 and GDF-15 Are Associated With Plasma Neurofilament Light Chain and Progranulin Among Community-Dwelling Older Adults
2023ArticleJournals of Gerontology Series A: Biological Sciences and Medical Sciences
Biomarkers of mitochondrial dysfunction and inflammaging in older adults and blood pressure variability
2023ArticleGeroScience
Prospective Associations of Plasma Growth Differentiation Factor 15 With Physical Performance and Cognitive Functions in Older Adults
2022ArticleJournals of Gerontology Series A: Biological Sciences and Medical Sciences
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Ouest-France · 07/06/2023
<a href="https://news.google.com/rss/articles/CBMihwJBVV95cUxQWkR5QXFYUWlhdElLSGRPMVdiVlFtVkF6MEtVR1AyV1hOT3RfRGpSdmFKa0ZVUVZpemtva1F4SWpFNDJQQUR2ZDNqemRCR3hWVUhCdzNqa1FfaWJfZW9McjQ4a0lHUlVEaGxWb3VDVl81OFFTaUxHNEdfb2VsX3lXeFJ3Qk9OZTZqN2pNNDJGOFVISkJHTFlFNTJqRVJqZWpVbDk4X1VkcmctOVlUbFJNRWZ1Z0JOSEFxa3
📰 Ouest-France · 19/04/2023
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPS1hZUnY1TUxIeVRFMl9DLVNZQWt0ZkdKQld5QnY5X1JKaWhvQ1ZVVjhKVFdGQjZQQjhpbG5iRkluZm1CeVJYVG10VXNubTlfQXB4OUwxUVIxdlQyeWlUSEtiV3pHbXluNF9RUFdNclhmR25DZG1rZHVObGNmLXBNcnFablNFeFd1cjJjVThwSnZwZmVjUmZocUxhdkNJaGdOWURwWGVwWUxJdnY3d2RXU1hwMm9mMHB0Yk
📰 Actu.fr · 28/02/2014
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOdTVHQnNweUVDY1VlMU5VXzNRR0ZHRzNSczVLTksyTXB6Snl5V2Y0Y0RkR1pwMnRrUmVLQ01sRDZvaFlRdW5FazQ3MEFZRGJ2dUE3RkJFbnM3dzJMdmpCLTVvc3Q5ckpTdnRVT2hrWEt5WUVHLUhsWkhFNHJrM2trVFpYSks3dklmYkw2dHNQUWJYYTZnVlE?oc=5" target="_blank">Municipales : la liste d
📰 Ouest-France · 30/10/2023
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxONWVWQ09EOXU5MHBTZEZiM0YydTBxbzh6ZUd4WDh1emxKcWNTUUFqNkVsRlktalZlYnBRQ2U1T213bWhoZ1hILWZsaG1FTUJmVnh1NEM4WXNLVHNkR3dkbzY0ZmFBeTVCc2ViYzJEcjhTenlNOVF6aHpORTVzc1RPdVAtRnRUNkpnc0w4N1dQLUk1RWhMS3ZFQ2pqZnB2bmhReklKc0RBWnhpMXBwWG9zeGtGZnNKRVZOQz
📰 Ouest-France · 02/02/2024
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxQeDQ5YXM0T3d0Z2lJcWhhUWh6UzYyLXZkOGZpc2c4UG1hcVZPdlBzQ0xUSHAwWHp0eGs3UlJwcDNRUnExNUJQMnJhLUxvQ1VWX09RUlR5RGR2TVdTWlhwSW1mY0VzcVpBNDRmSDItZmNuTjkxLWQxT3FIejdGbXVLVnN4TjdkZVpsRmp5bXdlNnAtVlVCeFBrVUpzaWJSWTlnQTlEdXAyNWZneGtiUFg0VERYeWFjelpKX0
📰 Ouest-France · 17/02/2020
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxPNjdHYmltd25zX044YUZlX1lGa2w2TktBcjNURDAwN3hockNjYzVHYU1uWWFCNEZtQzRicUx6VnphUUhRcTFJM0lORHJHdFhGSTlOV3IydDVvWFBGMkoxYkRwTHRDb0FqMzNDSy10RGlTQ1ZGZENMZXNRZ2VSektZSVNRVlVKenh6OFZXSWJsNzlmWWwxLTJGY2pEMnVtSDV2eUlkTlVOcktCekx0Z0NWTXV4cVNLSmhVem
European journal of pain (London, England) · 2006
AbstractBackground The Patient Assessment of Constipation Symptoms (PAC‐SYM) questionnaire is a 12‐item self‐report instrument divided into abdominal, rectal and stool domains.Aims This study aimed to (1) evaluate the psychometric properties of PAC‐SYM in assessing the symptoms and severity of opioid‐induced constipation; (2) test for differences in opioid‐induced constipation between Durogesic® fentanyl transdermal reservoir (TDF) and oral sustained‐release morphine (SRM) in patients with chronic low back pain (CLBP).Methods In a 13‐month, open‐label, parallel‐group study, 680 patients were randomised to receive either TDF (n = 338) or SRM (n = 342) for CLBP. Assessments were recorded at Visit 1 (baseline), Visit 5 (Day 29) and Visit 17 (Month 13). Concurrent validity, clinical validity and responsiveness of PAC‐SYM were determined based on patients' confirmation of constipation (CC) scores. Differences in PAC‐SYM scores between treatment groups were also evaluated.Results The study included 677 patients, of whom 638 were opioid‐naïve. Mean PAC‐SYM scores for constipated patients were substantially higher than for non‐constipated patients, demonstrating good clinical validity for PAC‐SYM. The PAC‐SYM could detect changes in bowel function over the treatment period, indicating responsiveness. Homogeneity of each symptom domain exceeded Cronbach's α coefficient of 0.70, suggesting good internal consistency and reliability. Changes in mean PAC‐SYM scores from baseline to Visit 5 and Visit 17 were significantly lower for the TDF group than for the SRM group, indicating that the TDF group experienced less severe constipation.Conclusion PAC‐SYM is a reliable, valid and responsive measure of the presence and severity of opioid‐induced constipation symptoms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2006
Purpose Bortezomib, a boronic acid dipeptide, has been recently introduced as a new approach to treating multiple myeloma (MM). The goal of this work was to evaluate the added value of patient-reported outcomes (PRO) in the interpretation of bortezomib clinical trial outcomes. Patients and Methods Two hundred two patients with relapsed, refractory MM were treated with bortezomib as part of the SUMMIT (Study of Uncontrolled Multiple Myeloma Managed with Proteasome Inhibition Therapy) study. Patients were administered the following four PRO measures at several time points: the European Organisation for Research and Treatment of Cancer (EORTC) core Quality of Life Questionnaire (QLQ-C30) and the myeloma-specific module (QLQ-MY24), the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue scale, and the Functional Assessment of Cancer Therapy (FACT)/Gynecologic Oncology Group (GOG) Neurotoxicity (Ntx) scale. Minimal important difference (MID) thresholds were used to define patients as improved, stable, or worsened. A survival analysis was conducted to assess the predictive power of PRO data. Results For the total population, there was a positive change between baseline and best end point. Consistent with the clinical responses, change in PRO scores showed statistically significant differences between response groups with PRO improvement in patients with complete response (CR) or partial response (PR), mostly stable scores in patients with minor response or no change, and deterioration in most scores for patients with progressive disease. Change in scores for neuropathy-related symptoms was reasonably stable. In contrast, fatigue scores significantly improved for patients with CR or PR. When various MID thresholds were applied, the proportion of improved patients exceeded 35% for several domains within all change group definitions. Moreover, survival analysis results demonstrated the additional prognostic information PRO data can provide to supplement clinical data. Conclusion This study demonstrated the complementary value for PRO assessments in further interpreting clinical response, the impact of adverse effects, and patient prognosis in clinical trials.
Clinical therapeutics · 2007
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Archives of pathology & laboratory medicine · 2025 · Journal Article
Baez-Navarro X, Riggi J, Zylberberg D, van der Made A, et al.
Frontiers in pharmacology · 2021 · Editorial
Silva H, Stonier P, Kerpel-Fronius S, Dubois D
Frontiers in pharmacology · 2018 · Journal Article
Kerpel-Fronius S, Becker S, Barrett J, Brun J, et al.
Pharmacology research & perspectives · 2015 · Journal Article
Lon HK, DuBois DC, Earp JC, Almon RR, et al.
Frontiers in pharmacology · 2014 · Published Erratum
Silva H, Stonier P, Buhler F, Deslypere JP, et al.
Frontiers in pharmacology · 2013 · Journal Article
Silva H, Stonier P, Buhler F, Deslypere JP, et al.
Journal of pharmacokinetics and pharmacodynamics · 2011 · Journal Article
Liu D, Lon HK, Dubois DC, Almon RR, et al.
PharmacoEconomics · 2010 · Journal Article
Gerlier L, Lamotte M, Wille M, Kreuz PC, et al.
Frontiers in pharmacology · 2015 · Journal Article
Ruano-Rodríguez C, Serra-Majem L, Dubois D
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2010 · Evaluation Study
Viala-Danten M, Dubois D, Gilet H, Martin S, et al.
HIV clinical trials · 2010 · Clinical Trial, Phase III
Drug metabolism and disposition: the biological fate of chemicals · 2017 · Journal Article
Li X, DuBois DC, Song D, Almon RR, et al.
Drug metabolism and disposition: the biological fate of chemicals · 2017 · Journal Article
Li X, DuBois DC, Almon RR, Jusko WJ
Drug metabolism and disposition: the biological fate of chemicals · 2017 · Journal Article
Li X, DuBois DC, Almon RR, Jusko WJ
Drug metabolism and disposition: the biological fate of chemicals · 2017 · Journal Article
Chen X, DuBois DC, Almon RR, Jusko WJ
Drug metabolism and disposition: the biological fate of chemicals · 2015 · Journal Article
Chen X, DuBois DC, Almon RR, Jusko WJ
Pharmaceutical research · 2011 · Journal Article
Lon HK, Liu D, Zhang Q, DuBois DC, et al.
American journal of public health · 2023 · Journal Article
Busch S, Andersen JA, Willis DE, McElfish PA, et al.
Medecine et maladies infectieuses · 2020 · Comparative Study
Bréhin C, Claudet I, Dubois D, Sales de Gauzy J, et al.
Journal of pediatric gastroenterology and nutrition · 2014 · Journal Article
The Journal of perinatal & neonatal nursing · 2024 · Journal Article
DuBois D, Sundell J, Thomsen MR, Brown CC
Current medical research and opinion · 2007 · Journal Article
Yang M, Dubois D, Kosinski M, Sun X, et al.
Clinical therapeutics · 2007 · Journal Article
Cole JC, Dubois D, Kosinski M
The Journal of pharmacology and experimental therapeutics · 2008 · Journal Article
Earp JC, Dubois DC, Molano DS, Pyszczynski NA, et al.
The Journal of pharmacology and experimental therapeutics · 2008 · Journal Article
Earp JC, Dubois DC, Molano DS, Pyszczynski NA, et al.
HIV clinical trials · 2010 · Clinical Trial, Phase III
Cella D, Gilet H, Viala-Danten M, Peeters K, et al.
The patient · 2008 · Journal Article
Gajria K, Kosinski M, Schein J, Kavanagh S, et al.
Pharmaceutical research · 2020 · Journal Article
Yu R, Li X, DuBois DC, Almon RR, et al.
The AAPS journal · 2019 · Comparative Study
Yu R, Song D, DuBois DC, Almon RR, et al.
Nutrition reviews · 2012 · Journal Article
Gyles CL, Lenoir-Wijnkoop I, Carlberg JG, Senanayake V, et al.
Clinical therapeutics · 2007 · Journal Article
Cole JC, Dubois D, Kosinski M
Journal of pharmacokinetics and pharmacodynamics · 2013 · Journal Article
Lon HK, Liu D, DuBois DC, Almon RR, et al.
Biopharmaceutics & drug disposition · 2013 · Comparative Study
Liu DY, Lon HK, Wang YL, DuBois DC, et al.
Current medical research and opinion · 2007 · Journal Article
Ward A, Bozkaya D, Fleischmann J, Dubois D, et al.
European journal of pain (London, England) · 2006 · Journal Article
Slappendel R, Simpson K, Dubois D, Keininger DL
Lupus · 2021 · Journal Article
Mendelsohn S, Khoja L, Alfred S, He J, et al.
Frontiers in pharmacology · 2015 · Journal Article
Nuijten MJ, Dubois DJ, Joseph A, Annemans L
Cella D, Gilet H, Viala-Danten M, Peeters K, et al.
Journal of clinical epidemiology · 2007 · Journal Article
Viala M, Bhakar AL, de la Loge C, van de Velde H, et al.
Clinical therapeutics · 2007 · Journal Article
Cole JC, Dubois D, Kosinski M
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2006 · Clinical Trial, Phase II
Dubois D, Dhawan R, van de Velde H, Esseltine D, et al.
Hartman EE, Pawaskar M, Williams V, McLeod L, et al.